Cipher Pharmaceuticals Past Earnings Performance
Past criteria checks 3/6
Cipher Pharmaceuticals has been growing earnings at an average annual rate of 54.6%, while the Pharmaceuticals industry saw earnings growing at 26.2% annually. Revenues have been declining at an average rate of 2.2% per year. Cipher Pharmaceuticals's return on equity is 25.3%, and it has net margins of 96.3%.
Key information
54.6%
Earnings growth rate
55.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | -2.2% |
| Return on equity | 25.3% |
| Net Margin | 96.3% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
There's No Escaping Cipher Pharmaceuticals Inc.'s (TSE:CPH) Muted Earnings Despite A 26% Share Price Rise
Mar 23
Weak Statutory Earnings May Not Tell The Whole Story For Cipher Pharmaceuticals (TSE:CPH)
Mar 22Here's Why I Think Cipher Pharmaceuticals (TSE:CPH) Is An Interesting Stock
May 14Analysts Just Published A Bright New Outlook For Cipher Pharmaceuticals Inc.'s (TSE:CPH)
May 18Cipher Pharmaceuticals Inc. Just Missed EPS By 37%: Here's What Analysts Think Will Happen Next
Mar 20Industry Analysts Just Upgraded Their Cipher Pharmaceuticals Inc. (TSE:CPH) Revenue Forecasts By 12%
Jan 26
Revenue & Expenses BreakdownBeta
How Cipher Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 21 | 20 | 5 | 0 |
| 30 Sep 23 | 21 | 32 | 6 | 0 |
| 30 Jun 23 | 20 | 28 | 6 | 0 |
| 31 Mar 23 | 20 | 27 | 6 | 0 |
| 31 Dec 22 | 21 | 27 | 5 | 0 |
| 30 Sep 22 | 22 | 10 | 5 | 0 |
| 30 Jun 22 | 21 | 8 | 5 | 0 |
| 31 Mar 22 | 22 | 9 | 5 | 0 |
| 31 Dec 21 | 22 | 8 | 5 | 0 |
| 30 Sep 21 | 22 | 5 | 6 | 0 |
| 30 Jun 21 | 23 | 6 | 6 | 0 |
| 31 Mar 21 | 21 | 3 | 6 | 0 |
| 31 Dec 20 | 22 | 4 | 6 | 0 |
| 30 Sep 20 | 21 | 7 | 6 | 0 |
| 30 Jun 20 | 22 | 3 | 5 | 0 |
| 31 Mar 20 | 23 | 4 | 6 | 0 |
| 31 Dec 19 | 22 | 3 | 8 | 0 |
| 30 Sep 19 | 23 | -1 | 11 | 0 |
| 30 Jun 19 | 22 | 2 | 13 | 0 |
| 31 Mar 19 | 23 | 3 | 14 | 1 |
| 31 Dec 18 | 23 | 1 | 14 | 1 |
| 30 Sep 18 | 28 | 6 | 13 | 1 |
| 30 Jun 18 | 34 | 9 | 13 | 0 |
| 31 Mar 18 | 37 | 11 | 13 | 0 |
| 31 Dec 17 | 40 | 11 | 13 | 0 |
| 30 Sep 17 | 34 | 7 | 13 | 0 |
| 30 Jun 17 | 32 | 5 | 13 | 0 |
| 31 Mar 17 | 31 | 1 | 14 | 1 |
| 31 Dec 16 | 30 | 4 | 16 | 1 |
| 30 Sep 16 | 33 | 6 | 23 | 1 |
| 30 Jun 16 | 34 | 2 | 28 | 0 |
| 31 Mar 16 | 34 | 1 | 29 | 0 |
| 31 Dec 15 | 34 | 2 | 29 | 1 |
| 30 Sep 15 | 32 | 3 | 21 | 1 |
| 30 Jun 15 | 30 | 13 | 14 | 1 |
| 31 Mar 15 | 30 | 18 | 10 | 1 |
| 31 Dec 14 | 29 | 19 | 9 | 1 |
| 30 Sep 14 | 33 | 31 | 7 | 1 |
| 30 Jun 14 | 32 | 27 | 7 | 1 |
| 31 Mar 14 | 29 | 25 | 7 | 0 |
| 31 Dec 13 | 25 | 24 | 6 | 0 |
| 30 Sep 13 | 17 | 9 | 6 | 0 |
| 30 Jun 13 | 13 | 6 | 5 | 0 |
Quality Earnings: CPH has high quality earnings.
Growing Profit Margin: CPH's current net profit margins (96.3%) are lower than last year .
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CPH's earnings have grown significantly by 54.6% per year over the past 5 years.
Accelerating Growth: CPH's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: CPH had negative earnings growth (-23.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (22%).
Return on Equity
High ROE: CPH's Return on Equity (25.3%) is considered high.